A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-28 and is reviewed periodically as new material appears.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
=== Patient support === Burn patients require support and care – both physiological and psychological. Respiratory failure, sepsis, and multi-organ system failure are common in hospitalized burn patients. To prevent hypothermia and maintain normal body temperature, burn patients with over 20% of burn injuries should be kept in an environment with the temperature at or above 30 degree Celsius. Metabolism in burn patients proceeds at a higher than normal speed due to the whole-body process and rapid fatty acid substrate cycles, which can be countered with an adequate supply of energy, nutrients, and antioxidants. Enteral feeding a day after resuscitation is required to reduce risk of infection, recovery time, non-infectious complications, hospital stay, long-term damage, and mortality. Controlling blood glucose levels can have an impact on liver function and survival. Risk of thromboembolism is high and acute respiratory distress syndrome (ARDS) that does not resolve with maximal ventilator use is also a common complication. Scars are long-term after-effects of a burn injury. Psychological support is required to cope with the aftermath of a fire accident, while to prevent scars and long-term damage to the skin and other body structures consulting with burn specialists, preventing infections, consuming nutritious foods, early and aggressive rehabilitation, and using compressive clothing are recommended.
=== Journey to Europe === For a few centuries, Europeans had experimented with American vines and plants in their soil. Many varieties were imported from America without regulation, disregarding the possibility of pest transfer and related problems. Jules-Emile Planchon, a French biologist who identified the Phylloxera in the 1860s, maintained that the transfer of American vines and plants into Europe greatly increased between roughly 1858 and 1862, and accidentally introduced Phylloxera to Europe around 1860. Others say that the aphid did not enter France until around 1863. The advent of steamships may have been a factor: as they were faster than sailing ships, the Phylloxera were better able to survive the shorter ocean voyage.
10 May Transgender woman Lexi-Rose Crawford is sentenced to 9 years in prison for raping a female victim, with the sentence to be served in a men's prison. The government confirms it will replace its plan for all EU-era legislation to expire at the end of 2023 with a list of 600 laws it wishes to replace. Vodafone confirms it will begin switching off its 3G network from June, prompting concerns that people with older and more basic phones could experience "digital poverty". The legal case Duke of Sussex v Mirror Group Newspapers begins at the High Court. Adam Price announces his resignation as leader of Plaid Cymru after a report found a culture of misogyny, harassment and bullying in the party. 11 May Wind power is reported as the main source of electricity generation in the UK for the first three months of the year, overtaking gas. The government announces that TransPennine Express will be stripped of its contract and nationalised, due to poor service and cancelled trains. The Bank of England raises its baseline interest rate for the 12th consecutive time, from 4.25% to 4.5%, increasing mortgage and loan costs, but increasing savings income for many. Defence Secretary Ben Wallace confirms that the UK will supply Storm Shadow cruise missiles to Ukraine, to assist the country in repelling the Russian invasion. These have a much longer range (250 km/155 mi) than US-supplied HIMARS missiles (80 km/50 mi).
Sources: en.wikipedia.org
== Chemistry == LGD-4033 is a nonsteroidal SARM with a pyrrolidinyl-benzonitrile core structure and is also referred to as a quinoline or quinolinone SARM. LG121071 (LGD-121071), a tricyclic quinoline, was the predecessor compound of LGD-4033. The chemical structure of LGD-4033 had not been disclosed as late as 2013. LGD-4033 has sometimes been confused with other structurally related Ligand Pharmaceuticals SARMs including LGD-2226, LGD-2941, and LGD-3303, but is a different compound from these agents. LGD-4033 is a small-molecule (molecular weight = 338.3 g/mol) and highly lipophilic (predicted log P = 3.6–3.7) compound.
In polymer chemistry, the molar mass distribution (or molecular weight distribution) describes the relationship between the number of moles of each polymer species (Ni) and the molar mass (Mi) of that species. In linear polymers, the individual polymer chains rarely have exactly the same degree of polymerization and molar mass, and there is always a distribution around an average value. The molar mass distribution of a polymer may be modified by polymer fractionation.
Impact factor data ... have a strong influence on the scientific community, affecting decisions on where to publish, whom to promote or hire, the success of grant applications, and even salary bonuses. More targeted research has begun to provide firm evidence of how deeply the impact factor is embedded within formal and informal research assessment processes. A review in 2019 studied how often the JIF featured in documents related to the review, promotion, and tenure of scientists in US and Canadian universities. It concluded that 40% of universities focused on academic research specifically mentioned the JIF as part of such review, promotion, and tenure processes. A 2017 study of how researchers in the life sciences behave concluded that "everyday decision-making practices as highly governed by pressures to publish in high-impact journals." It has been argued that the deeply embedded nature of such indicators not only affects research assessment, but the more fundamental issue of what research is actually undertaken: "Given the current ways of evaluation and valuing research, risky, lengthy, and unorthodox project rarely take center stage."
Sources: en.wikipedia.org
=== Potential risks === As BLCO contains materials like vanadium, nickel and PAH, those tend to be harmful and disturb possibility of antioxidant. Heavy metals are necessary in metabolic process of creatures; however, they are the causes of physiological stress at the same time. Pollution problems by oil spills like soils contamination are continuous and prevalent, putting severe health and environmental threats. The pollutants can gradually accumulate in food chains and interrupt biological actions of creatures. Petroleum contaminants are pernicious to nature and moreover, their hydrocarbon elements which are mutagenic and causing cancers, entail immunomodulatory impacts on humans and organisms as well. The symptoms of risks can appear immediately or emerge after some time.
Films generate income from several revenue streams, including theatrical exhibition, home video, television broadcast rights, and merchandising. However, theatrical box-office earnings are the primary metric for trade publications in assessing the success of a film, mostly because of the availability of the data compared to sales figures for home video and broadcast rights, but also because of historical practice. Included on the list are charts of the top box-office earners (ranked by both the nominal and real value of their revenue), a chart of high-grossing films by calendar year, a timeline showing the transition of the highest-grossing film record, and a chart of the highest-grossing film franchises and series. All charts are ranked by international theatrical box-office performance where possible, excluding income derived from home video, broadcasting rights, and merchandise. Traditionally, war films, musicals, and historical dramas have been the most popular genres, but franchise films have been among the best performers of the 21st century. There is strong interest in the superhero genre, with eleven films in the Marvel Cinematic Universe featuring among the nominal top-earners. The most successful superhero film, Avengers: Endgame, is also the second-highest-grossing film on the nominal earnings chart, and there are four films in total based on the Avengers comic books charting in the top twenty-five.
Lys-Gly-Asp-Glu-Glu-Ser-Leu-Ala was first determined by Yamasaki and Maekawa, who carried out the experiment using the Edman degradation method for N-terminus sequencing and carboxypeptidase A (Cpase A) and triazination methods for C-terminus sequencing. At the time of the experiment (1978), both methods were used in order to determine the amino acid composition and order of the sequence, including the discovery of a Glu-Glu linkage and the detection of alanine at the C-terminus. However, nowadays, either technique is sufficient to sequence the entire peptide.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.